QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
QQQ   359.61 (+0.47%)
AAPL   176.08 (+0.74%)
MSFT   317.54 (+0.17%)
META   300.83 (+0.59%)
GOOGL   131.11 (+0.66%)
AMZN   131.27 (+1.67%)
TSLA   246.99 (+0.86%)
NVDA   422.22 (+1.47%)
NIO   8.34 (-2.23%)
BABA   87.20 (-1.25%)
AMD   97.38 (+1.23%)
T   15.06 (-0.40%)
F   12.59 (+1.29%)
MU   68.58 (-0.44%)
CGC   0.94 (+11.86%)
GE   111.70 (+0.40%)
DIS   81.01 (-0.30%)
AMC   8.15 (+6.82%)
PFE   32.98 (+0.89%)
PYPL   58.86 (+1.69%)
NFLX   384.80 (+1.31%)
NASDAQ:VYGR

Voyager Therapeutics (VYGR) Stock Forecast, Price & News

$7.55
-0.05 (-0.66%)
(As of 09/25/2023 ET)
Compare
Today's Range
$7.40
$7.60
50-Day Range
$7.55
$10.23
52-Week Range
$4.77
$14.34
Volume
221,866 shs
Average Volume
459,213 shs
Market Capitalization
$331.45 million
P/E Ratio
3.33
Dividend Yield
N/A
Price Target
$17.00

Voyager Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
125.2% Upside
$17.00 Price Target
Short Interest
Bearish
5.98% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.62
Upright™ Environmental Score
News Sentiment
-0.14mentions of Voyager Therapeutics in the last 14 days
Based on 18 Articles This Week
Insider Trading
Selling Shares
$145,080 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From $1.11 to ($1.59) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.16 out of 5 stars

Medical Sector

433rd out of 961 stocks

Biological Products, Except Diagnostic Industry

68th out of 161 stocks


VYGR stock logo

About Voyager Therapeutics (NASDAQ:VYGR) Stock

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of Alzheimer's disease. It also develops VY-FXN01 to treat Friedreich's ataxia; superoxide dismutase 1 gene silencing program for the treatment of amyotrophic lateral sclerosis; and GBA1 gene replacement program to treat Parkinson's disease. In addition, the company develops research program for the treatment of Huntington's disease. It has collaboration and license agreements with Neurocrine Biosciences, Inc.; Pfizer Inc.; and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

VYGR Price History

VYGR Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Voyager's Danny Estrin shares 'devastating' cancer diagnosis
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
See More Headlines
Receive VYGR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Voyager Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VYGR Company Calendar

Last Earnings
8/03/2023
Today
9/25/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VYGR
Fax
N/A
Employees
125
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$17.00
High Stock Price Forecast
$18.00
Low Stock Price Forecast
$16.00
Forecasted Upside/Downside
+125.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-46,410,000.00
Pretax Margin
49.58%

Debt

Sales & Book Value

Annual Sales
$40.91 million
Book Value
$1.53 per share

Miscellaneous

Free Float
41,838,000
Market Cap
$331.45 million
Optionable
Optionable
Beta
1.03
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Alfred W. Sandrock Jr. (Age 65)
    M.D., Ph.D., Pres, CEO & Director
    Comp: $825.41k
  • Mr. Peter P. Pfreundschuh CPA (Age 54)
    Chief Financial Officer
    Comp: $172.73k
  • Dr. Krystof Bankiewicz M.D.
    Ph.D., Founder
  • Dr. Guangping Gao Ph.D.
    Founder & Member of Scientific Advisory Board
  • Dr. Mark A. Kay M.D. (Age 64)
    Ph.D., Founder
  • Dr. Phillip D. Zamore Ph.D.
    Founder & Member of Scientific Advisory Board
  • Ms. Robin Swartz (Age 52)
    Chief Operating Officer
  • Mr. Todd Carter Ph.D. (Age 53)
    Chief Scientific Officer
  • Ms. Jacquelyn Fahey Sandell Esq.
    J.D., Chief Legal Officer
  • Ms. Michelle Quinn Smith
    Chief HR Officer













VYGR Stock - Frequently Asked Questions

Should I buy or sell Voyager Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Voyager Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" VYGR shares.
View VYGR analyst ratings
or view top-rated stocks.

What is Voyager Therapeutics' stock price forecast for 2023?

3 analysts have issued 1-year price objectives for Voyager Therapeutics' stock. Their VYGR share price forecasts range from $16.00 to $18.00. On average, they predict the company's stock price to reach $17.00 in the next year. This suggests a possible upside of 125.2% from the stock's current price.
View analysts price targets for VYGR
or view top-rated stocks among Wall Street analysts.

How have VYGR shares performed in 2023?

Voyager Therapeutics' stock was trading at $6.10 at the start of the year. Since then, VYGR shares have increased by 23.8% and is now trading at $7.55.
View the best growth stocks for 2023 here
.

When is Voyager Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our VYGR earnings forecast
.

How were Voyager Therapeutics' earnings last quarter?

Voyager Therapeutics, Inc. (NASDAQ:VYGR) released its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.51) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.59) by $0.08. The business earned $4.85 million during the quarter, compared to analyst estimates of $2 million.

What ETF holds Voyager Therapeutics' stock ?

iShares Neuroscience and Healthcare ETF holds 4,243 shares of VYGR stock, representing 0.82% of its portfolio.

What other stocks do shareholders of Voyager Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Voyager Therapeutics investors own include Micron Technology (MU), REGENXBIO (RGNX), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Amarin (AMRN), CRISPR Therapeutics (CRSP), Inovio Pharmaceuticals (INO), Sangamo Therapeutics (SGMO) and Editas Medicine (EDIT).

What is Voyager Therapeutics' stock symbol?

Voyager Therapeutics trades on the NASDAQ under the ticker symbol "VYGR."

Who are Voyager Therapeutics' major shareholders?

Voyager Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (5.64%), Acadian Asset Management LLC (1.64%), Geode Capital Management LLC (1.34%), State Street Corp (1.24%), Marshall Wace LLP (1.07%) and JPMorgan Chase & Co. (0.81%). Insiders that own company stock include Alfred Sandrock, Allison Dorval, Andre Turenne, Ecor1 Capital, Llc, Glenn Pierce, Julie Burek, Neurocrine Biosciences Inc, Omar Khwaja, Robert W Hesslein, Robin Swartz, Rock Ventures Iii LP Third and Todd Alfred Carter.
View institutional ownership trends
.

How do I buy shares of Voyager Therapeutics?

Shares of VYGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Voyager Therapeutics' stock price today?

One share of VYGR stock can currently be purchased for approximately $7.55.

How much money does Voyager Therapeutics make?

Voyager Therapeutics (NASDAQ:VYGR) has a market capitalization of $331.45 million and generates $40.91 million in revenue each year. The company earns $-46,410,000.00 in net income (profit) each year or $2.27 on an earnings per share basis.

How many employees does Voyager Therapeutics have?

The company employs 125 workers across the globe.

How can I contact Voyager Therapeutics?

Voyager Therapeutics' mailing address is 75 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.voyagertherapeutics.com. The company can be reached via phone at (857) 259-5340 or via email at pcox@vygr.com.

This page (NASDAQ:VYGR) was last updated on 9/25/2023 by MarketBeat.com Staff

My Account -